NASDAQ$CAI
Caris Life Sciences Inc · Q2 2025 earnings
Q2 2025 earnings ·
Briefing
Caris Life Sciences reported Q2 2025, revenue of $163K, net income of $7M.
For Q2 2025, Caris Life Sciences reported revenue of $163K, net income of $7M. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.
- Revenue $163K.
- Net income $7M.
- Caris Life Sciences highlights operating priorities and capital allocation.
Headline financials
Revenue & EPS history
Caris Life Sciences Inc · Revenue · Quarterly
$181M
Forward guidance
The release discusses Caris Life Sciences's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- Caris Life Sciences cites demand and execution supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 3 quarterly earnings reports · overlaid with Q2 2025
-5.8%
Avg return
Earnings day
-8.5%
Avg return
5 days after
-3.7%
Avg return
30 days after
33%
1 / 3 earnings
Positive
+7.4%
Q2 2025
Best reaction
-18.6%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -18.6% | -26.0% | -16.8% | |
| Q3 2025 | -6.3% | -20.5% | -7.4% | |
| Q2 2025 | +7.4% | +20.8% | +13.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro